Across TCGA pan-cancer cohorts, NTF3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NTF3 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher NTF3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NTF3 expression acts as an unfavorable survival marker, although some lineages such as SKCM and LUSC show a favorable association.

THYM, SKCM, and LUSC are the cancer types where NTF3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	DFS	Median	All	0.123	0.871	<.001	12	view →
SKCM	DFS	Median	All	0.829	0.612	.034	5	view →
LUSC	DFS	Median	All	1.000	0.369	.043	3	view →
LUAD	OS	Median	All	0.294	0.673	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NTF3 tumor-vs-normal RNA expression · all NTF3 data types